In This Issue:

•Do the Opposite: Recent sentiment figures show plenty of fear, but the bears remain stubbornly cautious. They should know better.
•STARS Status: Changes in S&P analysts' STARS rankings for August 28 through September 1.
•Home Prices on Shaky Ground: A new S&P index indicates that home prices nationwide could fall 6% by May 2007.
•Royal Blue Chips: Stocks with above-average earnings growth and steadily increasing dividends can reward you with a princely sum over time.
•Drug Stocks Come Back to Life: Fund managers say the recent turnaround in pharmaceutical stocks is a sign of healthier times ahead. S&P Equity Strategy agrees.
•The Nurse Is In: Drugstore chains are branching out, and the investment implications are significant.
•Master List Stocks Update: Our three supervised Master List groups of stocks, recommended as core holdings for long-term investors, are regularly featured on these two pages. The Total Return Portfolio, highlighted this week, consists of stocks we like for income.
•Industry Momentum Portfolio: This S&P portfolio identifies industry sectors with potential for above-average price performance.

Some of the Companies Featured:

Abbott Laboratories
Advent Software
Bristol-Myers Squibb
Brown & Brown
Capital One
Crucell
Devon Energy
Enterprise GP Holdings
Global Payments
Home Depot
IndyMac
Lehman Brothers Holdings
Scottish Power
Semtech
SunTrust Banks

S&P Information Products

Browse S&P industry research products by category:

S&P Industry Surveys
S&P Industry Stock Reports
The Outlook
Search Engine Survey
Pocket Guides
Power Picks

About Standard & Poor's

Standard & Poor's is one of the world's preeminent providers of credit ratings, and for such globally recognized financial-market indices as the S&P 500®. S&P also provides a wide range of other products and services designed to help individuals and institutions around the world make better-informed financial decisions with greater confidence.